WallStreetZenWallStreetZen

NASDAQ: AFMD
Affimed Nv Stock

$6.86+0.33 (+5.05%)
Updated Jun 12, 2024
AFMD Price
$6.86
Fair Value Price
-$3.81
Market Cap
$103.79M
52 Week Low
$2.24
52 Week High
$8.95
P/E
-1.02x
P/B
2.37x
P/S
18.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.22M
Earnings
-$101.23M
Gross Margin
100%
Operating Margin
-2,416.71%
Profit Margin
-2,375.8%
Debt to Equity
0.74
Operating Cash Flow
-$110M
Beta
1.27
Next Earnings
Jun 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AFMD Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AFMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AFMD ($6.86) is overvalued by 280.04% relative to our estimate of its Fair Value price of -$3.81 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AFMD ($6.86) is not significantly undervalued (280.04%) relative to our estimate of its Fair Value price of -$3.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AFMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AFMD due diligence checks available for Premium users.

Be the first to know about important AFMD news, forecast changes, insider trades & much more!

AFMD News

Valuation

AFMD fair value

Fair Value of AFMD stock based on Discounted Cash Flow (DCF)
Price
$6.86
Fair Value
-$3.81
Undervalued by
280.04%
AFMD ($6.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AFMD ($6.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AFMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AFMD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.02x
Industry
-9.14x
Market
30.03x

AFMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.37x
Industry
6.31x
AFMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AFMD's financial health

Profit margin

Revenue
$168.5k
Net Income
-$20.8M
Profit Margin
-12,371%
AFMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AFMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$76.7M
Liabilities
$32.5M
Debt to equity
0.74
AFMD's short-term assets ($66.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AFMD's short-term assets ($66.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AFMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AFMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$25.9M
Investing
-$1.1k
Financing
-$453.3k
AFMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AFMD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AFMD$103.79M+5.05%-1.02x2.37x
ARMP$103.40M+4.38%-1.30x-1.83x
DBVT$101.26M+3.96%-1.28x0.91x
PDSB$107.47M+6.16%-2.14x2.89x
VTGN$99.72M-2.12%-2.43x0.87x

Affimed Nv Stock FAQ

What is Affimed Nv's quote symbol?

(NASDAQ: AFMD) Affimed Nv trades on the NASDAQ under the ticker symbol AFMD. Affimed Nv stock quotes can also be displayed as NASDAQ: AFMD.

If you're new to stock investing, here's how to buy Affimed Nv stock.

What is the 52 week high and low for Affimed Nv (NASDAQ: AFMD)?

(NASDAQ: AFMD) Affimed Nv's 52-week high was $8.95, and its 52-week low was $2.24. It is currently -23.35% from its 52-week high and 206.94% from its 52-week low.

How much is Affimed Nv stock worth today?

(NASDAQ: AFMD) Affimed Nv currently has 15,129,952 outstanding shares. With Affimed Nv stock trading at $6.86 per share, the total value of Affimed Nv stock (market capitalization) is $103.79M.

Affimed Nv stock was originally listed at a price of $57.00 in Sep 12, 2014. If you had invested in Affimed Nv stock at $57.00, your return over the last 9 years would have been -87.96%, for an annualized return of -20.96% (not including any dividends or dividend reinvestments).

How much is Affimed Nv's stock price per share?

(NASDAQ: AFMD) Affimed Nv stock price per share is $6.86 today (as of Jun 12, 2024).

What is Affimed Nv's Market Cap?

(NASDAQ: AFMD) Affimed Nv's market cap is $103.79M, as of Jun 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Affimed Nv's market cap is calculated by multiplying AFMD's current stock price of $6.86 by AFMD's total outstanding shares of 15,129,952.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.